These three compounds all belong to the GHRH side of the somatotropic axis, but they represent different design philosophies. Sermorelin is the reference point. Tesamorelin is the clinically validated stabilized analog. CJC-1295 represents a more heavily modified, extended-duration approach. That means the real comparison is not just peptide versus peptide — it is native-like versus stabilized versus long-duration design logic.

Longer duration may sound better until it becomes a confounder. Some protocols want pulsatile or shorter-window signaling because it more closely resembles the biology they are studying. Other protocols benefit from extended exposure because they are testing duration-dependent effects or want to reduce dosing frequency inside a model.

That is why no single GHRH analog is 'best' in all settings. The best one is the one whose modification profile fits the question.

Choose Sermorelin when you want the cleanest unmodified GHRH reference. Choose Tesamorelin when the protocol benefits from a more stable analog with the strongest evidence base. Choose CJC-1295 when long-acting modification itself is part of the research logic. If the question is really about synergy, move out of the GHRH-only bucket and compare against Ipamorelin or a combined stack instead.